NCT06769971

Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC

Phase II Study of Ivonescimab (PD1/VEGF Bispecific) and Cadonilimab（PDL1/CTLA4 Bispecific）in Combination with Etoposide and Carboplatin As First-line Therapy in Patients with Extensive Stage Small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Sichuan University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a phase II study. All patients are treatment naive extensive stage small cell lung cancer(ES-SCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of Ivonescimab and Cadonilimab in combination with chemotherapy in patients with ES-SCLC.

Conditions

• Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Ivonescimab	20mg/kg，IV infusion，Day1，Q3W
DRUG	Cadonilimab	10mg/kg，IV infusion，Day8，Q6W
DRUG	Etoposide	100mg/kg，IV infusion，Day1-3，Q3W
DRUG	Carboplatin	AUC 5，IV infusion，Day1，Q3W

Timeline

• Start date: 2025-02-01
• Primary completion: 2026-12-31
• Completion: 2027-12-31
• First posted: 2025-01-10
• Last updated: 2025-01-10

Locations

1 site across 1 country: China